Individuals are more reluctant to lose something they possess than to acquire something of value that they presently lack. This leads to a massive difference in how motivated they become to accomplish ...

The University of California has reclaimed its title as the world leader in influential, high-impact science, according to the 2025 Highly Cited Researchers List from data analytics firm Clarivate.

Selective Insurance Group has recently secured a 122,525-square-foot headquarters lease at 103 John F. Kennedy Parkway in Short Hills. The group plans to occupy the space in 2026. Cushman & Wakefield ...

In case you've faced some hurdles solving the clue, Praise highly, we've got the answer for you. Crossword puzzles offer a fantastic opportunity to engage your mind, enjoy leisure time, and test your ...

ScotusCrim is a recurring series by Rory Little focusing on intersections between the Supreme Court and criminal law. Please note that the views of outside contributors do not reflect the official ...

Selective Insurance announced last week it will transition its headquarters to Short Hills beginning in 2026. The insurance company will make the move from Branchville in Sussex County following a new ...

Last week, the nation was convulsed by another act of political violence, this time against a right-wing figure. While public figures across the spectrum denounced the act, it seems that right-wing ...

You may think your spouse’s "selective hearing" is a choice — but science argues otherwise. The phenomenon of selective hearing is more than choosing when or when not to listen, according to a recent ...

Crime sparks state of emergency in New Mexico: What we know Bodycam footage shows Powerball winner arrested after allegedly kicking deputy in face Car buyers beware, the market appears to be shifting ...

CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...

Preliminary efficacy results from an ongoing phase I/II trial of CTS2190, a PRMT1 inhibitor, in patients with advanced/metastatic solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO ...